Cresco Labs (CRLBF) Other Non-Current Assets (2019 - 2026)
Cresco Labs' (CRLBF) quarterly Other Non-Current Assets came in at $31.2 million in Q1 2026, up 84.74% YoY from $16.9 million in Q1 2025, and up 121.49% on a QoQ basis from $14.1 million in Q4 2025.
Cresco Labs (CRLBF) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 8 years of Other Non-Current Assets data on file, last reported at $31.2 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 84.74% year-over-year to $31.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.2 million (up 84.74% YoY) and the FY2025 annual result came in at $14.1 million, down 5.94% from the prior year.
- Other Non-Current Assets grew to $31.2 million in Q1 2026, from $14.1 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $33.3 million in Q3 2025 to a low of $2.3 million in Q3 2022.
- A 5-year average of $11.4 million and a median of $7.7 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 45.0% — and 2025, when it soared 354.13%.
- Tracing CRLBF's Other Non-Current Assets over 5 years: stood at $9.4 million in 2022, then slumped by 36.64% to $6.0 million in 2023, then surged by 150.67% to $15.0 million in 2024, then fell by 5.94% to $14.1 million in 2025, then surged by 121.49% to $31.2 million in 2026.
- The last three Other Non-Current Assets figures came in at $31.2 million (Q1 2026), $14.1 million (Q4 2025), and $33.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | Cresco Labs | 295.09 Mn | 230.98 Mn | 86.95 Mn | 31.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.23 Mn |
| Dec 31, 2025 | 14.10 Mn |
| Sep 30, 2025 | 33.29 Mn |
| Jun 30, 2025 | 13.90 Mn |
| Mar 31, 2025 | 16.90 Mn |
| Dec 31, 2024 | 14.99 Mn |
| Sep 30, 2024 | 7.33 Mn |
| Jun 30, 2024 | 7.57 Mn |
| Mar 31, 2024 | 7.71 Mn |
| Dec 31, 2023 | 5.98 Mn |
| Sep 30, 2023 | 5.88 Mn |
| Jun 30, 2023 | 4.98 Mn |
| Mar 31, 2023 | 9.92 Mn |
| Dec 31, 2022 | 9.44 Mn |
| Sep 30, 2022 | 2.28 Mn |
| Jun 30, 2022 | 4.22 Mn |
| Mar 31, 2022 | 4.21 Mn |
| Dec 31, 2021 | 4.21 Mn |
| Sep 30, 2021 | 4.14 Mn |
| Jun 30, 2021 | 4.19 Mn |